Clinical characteristics and frequency of autoantibodies in patients with Systemic Lupus Erythematosus who attend the National Hospital in the period 2018 -2023
DOI:
https://doi.org/10.52379/mcs.v9.577Keywords:
Systemic lupus erythematosus, autoantibodies, clinical manifestationsAbstract
Introduction: Systemic lupus erythematosus (SLE) is characterized by immune system dysfunction and presents renal, dermatological, neuropsychiatric, and cardiovascular symptoms. Biomarkers play a key role in improving SLE diagnosis, evaluation, and control. Objective: To determine the clinical characteristics and frequency of autoantibodies in patients with SLE hospitalized at the National Hospital of Itauguá between 2018 and October 2023. Methodology: Descriptive, observational, cross-sectional study with an analytical component that included patients with SLE hospitalized at the National Hospital of Itauguá. Demographic and clinical characteristics, and the presence of autoantibodies (anti-DNA, anti-Sm, anti-RNP, anti-Ro, anti-La, anti-Jo, rheumatoid factor, anti-ribosomal factor, anti-histone, anticardiolipin, and lupus anticoagulant) were analyzed. Descriptive statistics and the chi square test were used at a significance level of 0.05 to establish associations. Results: 164 patients between 13 and 87 years of age (median: 28.5) were included, 87% were female, 53% from the Central Department. 51.8% of the patients had severe disease activity, among the most frequent manifestations were alopecia (81.7%), arthralgia (75.6%), headache (67.7%), malar erythema (58.5%), arthritis (34.8%) and in the proportion (31,7%) nephritis and prolonged fever. Anti-DNA was present in 59.8% (n=98), FR 23.78% (n=39), anti-Ro 43.90% (n=72), anti-Sm 32.32% (n=53), anti-RNP 23.8% (n=39), anti-La 17.68% (n=29), anti p ribosomal 13.41% (n=22), anti-centromere 4.88% (n=8), anti SL70 2.44% (n=4), anti-histone 9.76% (n=16), anti-cardiolipin 7.3% (n=12), lupus anticoagulant 8.54% (n=14). Anti-DNA, anti-rnp and anti-p ribosomal autoantibodies were significantly associated with nephritis; and anti Sm with Reyunad syndrome. Conclusion. A high prevalence of severe disease activity was identified in SLE patients, with predominant symptoms such as alopecia and arthralgia. The most frequent autoantibodies were anti-DNA, anti-Ro, and anti-Sm, with significant associations with nephritis and Raynaud’s syndrome. These findings highlight the importance of biomarkers in SLE management.
Downloads
References
1. Gómez-Bañuelos E, Fava A, Andrade F. An update on autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2023;35(2):61-67. https://doi.org/10.1097/BOR.0000000000000922
2. Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172(11):ITC81-ITC96. https://doi.org/10.7326/AITC202006020
3. Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021;11(7):928. https://doi.org/10.3390/biom11070928
4. Zucchi D, Silvagni E, Elefante E, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023;41(5):997-1008. https://doi.org/10.55563/clinexprheumatol/4uc7e8
5. Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: An update. Autoimmun Rev. 2024;23(10):103648. https://doi.org/10.1016/j.autrev.2024.103648
6. Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Int J Mol Sci. 2023;24(7):6578. https://doi.org/10.3390/ijms24076578
7. Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. https://doi.org/10.1016/j.jaut.2022.102871
8. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. https://doi.org/10.1002/art.40930
9. Reátegui-Sokolova C, Ugarte-Gil MF, Harvey GB, et al. Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). RMD Open. 2020;6(3):e001299. https://doi.org/10.1136/rmdopen-2020-001299
10. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. https://doi.org/10.1136/ard-2023-224762
11. Ahn SS, Jung SM, Yoo J, Lee SW, Song JJ, Park YB. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol Int. 2019;39(11):1937-1944. https://doi.org/10.1007/s00296-019-04445-y
12. Dima A, Jurcut C, Baicus C. The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int. 2018;38(7):1169-1178. https://doi.org/10.1007/s00296-018-4059-4
13. Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun. 2020;110:102356. https://doi.org/10.1016/j.jaut.2019.102356
14. Meroni PL, Tsokos GC. Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Front Immunol. 2019;10:199. https://doi.org/10.3389/fimmu.2019.00199
15. Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023;82(8):999-1014. https://doi.org/10.1136/ard-2022-223741
16. Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. 2024;331(24):2136]. JAMA. 2024;331(17):1480-1491. https://doi.org/10.1001/jama.2024.2315
17. Lou H, Ling GS, Cao X. Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. J Autoimmun. 2022;132:102861. https://doi.org/10.1016/j.jaut.2022.102861
18. Alforaih N, Whittall-Garcia L, Touma Z. A Review of Lupus Nephritis. J Appl Lab Med. 2022;7(6):1450-1467. https://doi.org/10.1093/jalm/jfac036
19. Lai NS, Lu MC, Chang HH, Lo HC, Hsu CW, et al. Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life. J Clin Med. 2021;10(10):2137. https://doi.org/10.3390/jcm10102137
20. Walace D. Clinical manifestations and diagnosis of systemic lupus erythematosus in adults. UpToDate. 2023.
21. Renée SD, Mercado U. Características clínicas e inmunológicas de lupus eritematoso sistémico aplicando los criterios de clasificación de EULAR/ACR 2019. Med Int Mex. 2022;38(3):507-513. https://doi.org/10.24245/mim.v38i3.5146
22. Maloney KC, Ferguson TS, Stewart HD, Myers AA, De Ceulaer K. Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis. Lupus. 2017;26(13):1448-1456. https://doi.org/10.1177/0961203317707828
23. Moriano C, Bellido-Pastrana D, San Román Gutiérrez C, Rodríguez E. Evolution of diagnosis and treatment for lupus nephritis in Spain. Nefrologia (Engl Ed). 2023;43(6):668-675. https://doi.org/10.1016/j.nefroe.2023.12.006
24. Heimovski FE, Simioni JA, Skare TL. Systemic lupus erythematosus and Raynaud's phenomenon. An Bras Dermatol. 2015;90(6):837-840. https://doi.org/10.1590/abd1806-4841.20153881
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Luis Fernando Sánchez, Dora Montiel-Jarolin, Magali Jarolin Montiel, Margarita Samudio
This work is licensed under a Creative Commons Attribution 4.0 International License.
